CytoTronics
CytoTronics developed the Pixel platform, a semiconductor-based live-cell analysis system using CMOS microelectrode arrays embedded in microplates to deliver label-free, multi-modal cell measurements at single-cell resolution for pharmaceutical, biotech, and academic drug discovery customers, prior to its January 2026 acquisition by Axion BioSystems.
- Company typePrivate
- Founded2021
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CytoTronics does
CytoTronics, Inc. was a privately held Boston-based life sciences tools company founded in 2021 as a Harvard University spin-off that developed the Pixel platform, a semiconductor-based live-cell analysis system using CMOS (Complementary Metal-Oxide-Semiconductor) microelectrode arrays embedded at the base of standard 96- and 384-well microplates. Each well contained over 100,000 nanoscale electrode-based sensors enabling thousands of simultaneous, label-free, multi-modal measurements (viability, morphology, electrophysiology, metabolism, barrier function) at single-cell resolution, with the company marketing more than 13 million sensors across its plate formats. The product family comprised the entry-level Pixel Primo single-plate reader (starting list price under $30,000), the high-throughput Pixel Octo eight-plate reader with integrated benchtop incubator, proprietary Pixel Plates as recurring consumables, and the cloud-based Pixel Pro control and analysis software, supported by vertical application modules for Neural (April 2025) and Cardiac (May 2025) research.
The company's commercial model combined direct enterprise sales, an early access/Try Before You Buy program, and scientific marketing through conferences (SLAS, ISSCR, Neuroscience), targeting pharmaceutical and biotech drug discovery teams, academic and research institutions, and stem cell/iPSC-derived cell providers, with 40+ collaborator sites across 7 countries by late 2024. CytoTronics raised $22.75M in aggregate seed funding (April 2022 and September 2024) and earned the SLAS 2024 New Product Award and R&D 100 Award in 2024. In January 2026, Axion BioSystems acquired CytoTronics' intellectual property and assets, terminating CytoTronics as an independent operating company and rolling the Pixel platform into Axion's existing MEA-focused distribution network.
CytoTronics firmographics
Firmographics- Name
- CytoTronics
- Legal name
- CytoTronics, Inc.
- Website
- https://cytotronics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- CytoTronics developed the Pixel platform, a semiconductor-based live-cell analysis system using CMOS microelectrode arrays embedded in microplates to deliver label-free, multi-modal cell measurements at single-cell resolution for pharmaceutical, biotech, and academic drug discovery customers, prior to its January 2026 acquisition by Axion BioSystems.
- Ownership category
- akta.pro rank
CytoTronics industry classification
Industry- Product category
- Live-Cell Analysis Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515), Semiconductor and Other Electronic Component Manufacturing (33441)
- SIC
- Laboratory Analytical Instruments (3826), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)
- akta.pro primary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
- akta.pro secondary industries
- Sensors, MEMS & Imaging ICs (HDAHAAAG), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Imaging Sensors (CMOS/CCD/ToF/Depth) (HDAHALAF)
Keywords
Where CytoTronics is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CytoTronics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pixel Instruments and Plates: CytoTronics sells Pixel Primo and Pixel Octo instruments along with proprietary Pixel plates (96- and 384-well format) embedded with semiconductor microchips. Starting list price under $30K USD for Pixel Primo.
- Software/SaaS (Pixel Pro): Cloud-based Pixel Pro software for control and data analysis, likely offered as subscription or included with hardware purchase
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Pixel Primo entry-level system |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
CytoTronics product offering
Product offeringCore offering
CytoTronics designs and commercializes the Pixel platform — semiconductor-based live-cell analysis systems that integrate CMOS microelectrode arrays into standard 96- and 384-well microplates. The platform includes the Pixel Primo single-plate reader, the Pixel Octo 8-plate high-throughput reader with integrated incubator, proprietary Pixel Plates consumables with over 100,000 nanoscale electrode sensors per well, and cloud-based Pixel Pro software. The system captures 20+ cellular parameters including viability, morphology, electrophysiology, and metabolism simultaneously, enabling drug discovery and cell biology research at single-cell resolution without labels or dyes.
Product overview
CytoTronics offers the Pixel platform, a semiconductor-based live-cell analysis system for cell biology discovery. The core Pixel platform consists of Pixel Primo (entry-level single plate reader starting under $30K) and Pixel Octo (high-throughput 8-plate reader with integrated benchtop incubator), both using proprietary Pixel Plates (96- or 384-well microplates with semiconductor microchips containing over 100,000 nanoscale electrode-based sensors per well). Cloud-based Pixel Pro software enables measurement control and data analysis. The platform delivers simultaneous multi-modal readouts of cell viability, morphology, electrophysiology, metabolism, and barrier function with single-cell resolution via electrical imaging technology. Specialized application modules including Neural Application (for neurological disease and neurotoxicity research) and Cardiac Application (for cardiovascular research and cardiotoxicology) extend the platform for specific therapeutic areas.
Differentiator
Problem solved
Functional benefit
Brands
- Pixel: Semiconductor-based platform for live cell analysis enabling high-resolution monitoring of live cells with single-cell resolution across all cell types. Includes Pixel Primo (single plate reader) and Pixel Octo (8-plate benchtop system).
- Pixel Pro
Products and services
- Pixel Primo Entry-level single plate reader for the Pixel platform that fits in any standard cell culture incubator. Reads one 96- or 384-well Pixel plate at a time, enabling semiconductor-based live-cell analysis with thousands of multi-modal measurements per well at single-cell resolution. Targeted at biotech, pharma, and academic researchers.
- Pixel Octo High-throughput 8-plate reader and benchtop incubator with integrated environmental control for temperature, CO2, humidity, and oxygen. Reads up to eight 96- or 384-well Pixel plates simultaneously and pairs with laboratory robotic automation for industrial-scale screening of tens of thousands of wells in parallel. Targeted at pharma and biotech screening operations.
- Pixel Plates Proprietary 96- or 384-well microplates embedded with custom-designed semiconductor microchips at the base of each well. Each well contains over 100,000 nanoscale electrode-based sensors enabling thousands of measurements per well on any cell type, spheroid, or 3D organoid system. Consumable used with Pixel Primo and Pixel Octo instruments.
- Pixel Pro Cloud-based control and interactive analysis software for Pixel systems. Enables measurement design, experiment execution, real-time data access from anywhere, and sophisticated data analysis tools for high-dimensional live cell measurements across viability, morphology, electrophysiology, metabolism, and barrier function.
- Pixel Neural Application First-of-its-kind application combining electrical imaging with electrophysiology to simultaneously measure neural structure and activity at scale in 96- and 384-well plates with up to 144 recording channels per well. Used for drug discovery in neurological disease, neurotoxicity research, and neurodegenerative disease applications including Parkinson's, Alzheimer's, ALS, and blood-brain barrier studies.
- Pixel Cardiac Application Multi-modal application measuring cardiomyocyte electrical activity, contractility, and cell morphology simultaneously in a single multiplexed assay at scale in 96- and 384-well plates. Enables cardiovascular disease research and cardiotoxicology studies with real-time monitoring of acute and chronic compound responses.
Quantifiable outcome
- Captures over 100,000 measurements per well across 20+ cellular parameters
- +3 more outcomes
Companies that use CytoTronics
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles3 records
CytoTronics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature7 records
CytoTronics partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and flagship.
- Axol BiosciencecoreActive collaboration for cell supply in neurodegenerative disease and neurotoxicity research. Axol provides iPSC-derived cells used with Pixel for applications in Parkinson's, Alzheimer's disease, ALS, blood-brain barrier/CNS function, and pain research.
- AnatomiccoreActive collaboration for cell and organoid supply requiring sophisticated cell characterization that Pixel enables for disease research.
- BrainXellcoreActive collaboration providing neuronal cells for research applications. BrainXell cells used in Pixel applications for neural function studies and blood-brain barrier modeling.
- Trailhead BiosystemscoreActive collaboration for organoid supply and disease modeling applications requiring Pixel's cell characterization capabilities.
- ACROBiosystemscoreCollaboration site for cardiovascular research and cardiotoxicology applications using Pixel's Cardiac application.
- FUJIFILM Cellular DynamicscoreCollaboration providing iPSC-derived cardiomyocytes for cardiac disease modeling and Pixel applications. Human iPSC-derived glutamatergic neurons also used for neural studies.
- InSpherocoreCollaboration for 3D cell models (organoids/spheroids) used in cardiotoxicology and disease research with Pixel systems.
- NcardiacoreCollaboration for iPSC-derived cells for cardiovascular disease research and cardiac applications using Pixel platform.
- Stanford UniversitycoreCollaboration with Dr. Ioannis Karakikes studying cardiac disease phenotypes and genetic mutations in cardiomyopathies. Stanford is part of the international PRIORITY consortium for cardio-laminopathy research.
- Harvard Medical SchoolcoreCollaboration site for research activities. CytoTronics originated from Harvard University research.
- Harvard Chemistry & Chemical BiologycoreCollaboration site for research activities. Original research foundation was developed in Harvard labs.
- Axion BioSystemsflagshipIn January 2026, Axion BioSystems acquired CytoTronics' intellectual property and assets including high-density CMOS MEA technology. Co-founder Jeffrey Abbott transitioned to Vice President at Axion. Axion commercializes the technology through their existing distribution network.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
CytoTronics competitors and assessment
Company assessmentDirect peers
- Axion BioSystems: Axion BioSystems manufactures multi-well MEA platforms (Maestro) for neural and cardiac activity monitoring. It is the closest direct peer in microplate-format MEA electrophysiology and is now CytoTronics' acquirer, making it both a competitor and commercial vehicle for the Pixel technology.
- MaxWell Biosystems: MaxWell Biosystems develops high-density CMOS microelectrode array chips (MaxOne, MaxTwo) for single-cell and network-level electrophysiology. It is a direct peer in CMOS-MEA technology for live-cell functional readouts with comparable single-neuron resolution.
- Multi Channel Systems (Harvard Bioscience): Multi Channel Systems, a Harvard Bioscience company, supplies MEA platforms and MEA-based live-cell recording instruments used in cardiac and neural safety pharmacology. It competes head-to-head with Pixel in microplate-format electrophysiology screening.
- Nanion Technologies: Nanion Technologies makes planar patch-clamp and MEA instruments for ion-channel research and cardiac safety screening (e.g., CardioExcyte 96). It is a direct peer in electrophysiology instrumentation targeting the same drug-discovery and safety-pharmacology customers.
- Molecular Devices: Molecular Devices (a Danaher operating company) produces high-content screening imagers and electrophysiology readers used in drug discovery. It overlaps with Pixel in label-free, high-throughput functional cell analysis for pharma research workflows.
- ACEA Biosciences (xCELLigence, now part of Agilent): ACEA's xCELLigence real-time cell analysis system uses impedance-based readouts in microplate formats to monitor cell viability, morphology, and proliferation. It is a direct competitor in label-free, kinetic live-cell analysis targeting the same drug-discovery and toxicology use cases as Pixel.
Broad incumbents
- Thermo Fisher Scientific: Thermo Fisher Scientific is a global life-sciences tools incumbent offering cell-analysis instruments, consumables, and informatics. It competes broadly with Pixel through its laboratory products division for pharma and academic research budgets.
- Sartorius: Sartorius provides cell-analysis and bioprocessing instruments used in drug discovery and cell-line development. It is a broad incumbent whose cell-analysis portfolio addresses overlapping pharma and biotech customers as Pixel.
- Bruker: Bruker's life-science cell-analysis products include high-content imaging and microscopy instruments used by pharma and academic researchers. It is a broad incumbent in analytical cell-biology instrumentation competing for similar R&D dollars.
Emerging players
- Standard BioTools (formerly Fluidigm): Standard BioTools produces mass cytometry and single-cell genomics platforms (Helios, Hyperion) for deep cellular profiling. It is an emerging player in high-dimensional single-cell analysis with partial overlap to Pixel's high-parameter, single-cell resolution positioning in pharma research.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
CytoTronics social profiles
Digital presenceCytoTronics financial estimates
Financial estimateRevenue estimate
Valuation estimate
CytoTronics leadership team
Management profileNumber of profiles
Profiles15 records
CytoTronics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CytoTronics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CytoTronics
What does CytoTronics do?
CytoTronics designs and commercializes the Pixel platform — semiconductor-based live-cell analysis systems that integrate CMOS microelectrode arrays into standard 96- and 384-well microplates. The platform includes the Pixel Primo single-plate reader, the Pixel Octo 8-plate high-throughput reader with integrated incubator, proprietary Pixel Plates consumables with over 100,000 nanoscale electrode sensors per well, and cloud-based Pixel Pro software. The system captures 20+ cellular parameters including viability, morphology, electrophysiology, and metabolism simultaneously, enabling drug discovery and cell biology research at single-cell resolution without labels or dyes.
Is CytoTronics a public or private company?
CytoTronics is a private company. It is classified as corporate owned and is currently acquired.
When was CytoTronics founded?
CytoTronics was founded in 2021. It employs 11 to 50 people.
Where is CytoTronics based?
CytoTronics is headquartered in Boston, United States, in the North America region.
How does CytoTronics make money?
Two revenue lines are on record. Pixel Instruments and Plates are the primary driver. The others are software/SaaS (Pixel Pro).
Who are CytoTronics's main competitors?
Direct peers on record are Axion BioSystems, MaxWell Biosystems, Multi Channel Systems (Harvard Bioscience), Nanion Technologies, Molecular Devices and ACEA Biosciences (xCELLigence, now part of Agilent). Broad incumbents are Thermo Fisher Scientific, Sartorius and Bruker. Standard BioTools (formerly Fluidigm) is listed as an emerging player.
Does CytoTronics have an API?
No public API is recorded for CytoTronics.
What industry is CytoTronics in?
CytoTronics's product category is Live-Cell Analysis Instruments. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HDAHAAAG, Sensors, MEMS & Imaging ICs. Its NAICS code is 334516 and its SIC code is 3826.